Form 4: Charles River Labs COO Gains Shares, Shifts Holdings
Insider Transaction Report
Charles River Laboratories' COO, Birgit Girshick, acquired 9,500 shares through performance awards and transferred 45,470 shares to a revocable trust.
Summary
- Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories International, Inc. (CRL), reported changes in her beneficial ownership.
- Acquired 9,500 shares of common stock on January 30, 2026, resulting from the achievement of performance goals for awards granted on May 26, 2023.
- Disposed of 3,061 shares of common stock on January 30, 2026, at a price of $211.68 per share, likely for tax withholding purposes related to the performance share vesting.
- Transferred 45,470 shares of common stock from direct ownership to a revocable trust controlled by the reporting person, an exempt transaction under Rule 16a-13.
- Following these transactions, direct beneficial ownership stands at 26,913 shares, and indirect beneficial ownership through the revocable trust is 45,470 shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing as moderately positive. The acquisition of shares due to performance goal achievement signals management's successful execution and alignment with shareholder interests, while the disposition for tax purposes and transfer to a trust are routine and neutral events.
Positives
- Birgit Girshick acquired 9,500 shares of common stock due to the achievement of performance goals, indicating successful execution against pre-set targets.
Negatives
- Disposed of 3,061 shares of common stock at $211.68 per share, likely for tax obligations, which reduces direct holdings.
Industry Context
StockSavvy.ai notes that routine insider transactions, such as the vesting of performance-based awards and subsequent tax-related dispositions, are common across the life sciences and pharmaceutical services industry. The transfer of shares to a revocable trust is a standard estate planning practice for executives.
Stakeholder Impact
- Shareholders: The acquisition of shares by a key executive through performance awards may be viewed positively, indicating management's confidence and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 05/26/2023 | Original grant date of performance share unit awards. |
| 01/30/2026 | Date of common stock acquisition due to performance goal achievement. |
| 01/30/2026 | Date of common stock disposition for tax purposes. |
| 01/30/2026 | Date of common stock transfer to a revocable trust. |
| 02/02/2026 | Signature date of the reporting person on the Form 4 filing. |
Keywords
Charles River Laboratories, CRL, Insider Transaction, Form 4, Beneficial Ownership, Performance Share Units, Executive Compensation, Birgit Girshick
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.